Beijing VDJBio Co., LTD. (hereinafter referred to as "the Company" or "Weidejie") focuses on developing best-in-class innovative antibody drugs for autoimmune diseases. Weidejie is a National High-Tech Enterprise and a Beijing Specialized, Refined, Distinctive, and Innovative SME. It is a key entity responsible for major national and Beijing Municipal Science and Technology Commission (BSTC) initiatives in new drug creation, a BSTC-supported key innovative R&D enterprise in the pharmaceutical and healthcare sector, and has received government funding support from initiatives such as the Zhongguancun Frontier and the Haidian District Pharmaceutical and Health Development Special Projects. In recent years, the Company has received honors including the "2023 Capital Engineering Innovation Practice Top Ten Cases," the "2024 Zhongguancun Forum Top 100 New Technologies and Products List," the Most Promising Award at the "2024 China · Haidian High-Value Patent Cultivation Competition," and the Third Prize in the Overseas Returnees Entrepreneurship Competition. 

 The Company possesses a unique, internationally leading antibody affinity enhancement platform that simulates the human antibody maturation mechanism, as well as a comprehensive small-scale, pilot-scale, and industrial-scale production platform for macromolecular drugs. Leveraging these platform advantages, the Company has developed a series of antibody/fusion protein drugs with best-in-class potential for treating autoimmune diseases. Currently, three products have entered the clinical stage, covering four indications, one product has received clinical approval, and the first antibody industrial production base matching the products has been put into operation, completing process transfer and scale-up, and obtaining approval from the Center for Drug Evaluation (CDE) for clinical trial samples. The Company also has multiple preclinical research programs covering mainstream targets in autoimmune diseases and rare diseases, with candidate drugs including monoclonal antibodies, bispecific antibodies, multi-specific antibodies, fusion proteins, and ADCs, each with distinct features and strong competitiveness. All the Company's research products have applied for domestic and international invention patents, with multiple authorizations granted in countries such as China, the United States, Japan, and South Korea. 

 Beijing VDJBio Co., LTD. possesses comprehensive end-to-end technologies for antibody drug development and production, positioning it as an innovative biopharmaceutical enterprise with an established scale. The Company's rich pipeline aims to provide better treatment options and more comprehensive drug choices for patients with autoimmune diseases and rare diseases.